NASDAQ:ATRC

AtriCure (ATRC) Stock Price, News & Analysis

$23.17
+0.46 (+2.03%)
(As of 04/23/2024 ET)
Today's Range
$23.12
$24.17
50-Day Range
$22.71
$37.78
52-Week Range
$22.27
$59.61
Volume
947,750 shs
Average Volume
685,555 shs
Market Capitalization
$1.12 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$52.63

AtriCure MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
127.1% Upside
$52.63 Price Target
Short Interest
Bearish
6.72% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.01mentions of AtriCure in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$468,797 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.71) to ($0.47) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.45 out of 5 stars

Medical Sector

633rd out of 910 stocks

Surgical & Medical Instruments Industry

68th out of 95 stocks

ATRC stock logo

About AtriCure Stock (NASDAQ:ATRC)

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

ATRC Stock Price History

ATRC Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
AtriCure (NASDAQ:ATRC) Sets New 1-Year Low at $22.42
Short Interest in AtriCure, Inc. (NASDAQ:ATRC) Rises By 9.4%
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
ATRC May 2024 30.000 call
ATRC Apr 2024 22.500 put
AtriCure (ATRC) Fell on Competitor Action
AtriCure Full Year 2023 Earnings: EPS Beats Expectations
AtriCure price target raised by $1 at UBS, here's why
Cracking The Code: Understanding Analyst Reviews For AtriCure
Recap: AtriCure Q4 Earnings
AtriCure Q4 2023 Earnings Preview
See More Headlines
Receive ATRC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AtriCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/15/2024
Today
4/23/2024
Next Earnings (Confirmed)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:ATRC
CUSIP
04963C20
Employees
1,200
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$52.63
High Stock Price Target
$68.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+127.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-30,440,000.00
Pretax Margin
-7.48%

Debt

Sales & Book Value

Annual Sales
$399.24 million
Book Value
$9.84 per share

Miscellaneous

Free Float
46,827,000
Market Cap
$1.12 billion
Optionable
Optionable
Beta
1.38

Social Links

Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

ATRC Stock Analysis - Frequently Asked Questions

Should I buy or sell AtriCure stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ATRC shares.
View ATRC analyst ratings
or view top-rated stocks.

What is AtriCure's stock price target for 2024?

6 Wall Street analysts have issued 1 year price objectives for AtriCure's stock. Their ATRC share price targets range from $32.00 to $68.00. On average, they predict the company's share price to reach $52.63 in the next twelve months. This suggests a possible upside of 127.1% from the stock's current price.
View analysts price targets for ATRC
or view top-rated stocks among Wall Street analysts.

How have ATRC shares performed in 2024?

AtriCure's stock was trading at $35.69 at the beginning of the year. Since then, ATRC stock has decreased by 35.1% and is now trading at $23.17.
View the best growth stocks for 2024 here
.

Are investors shorting AtriCure?

AtriCure saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,250,000 shares, an increase of 9.4% from the March 15th total of 2,970,000 shares. Based on an average daily volume of 668,700 shares, the short-interest ratio is currently 4.9 days.
View AtriCure's Short Interest
.

When is AtriCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our ATRC earnings forecast
.

How can I listen to AtriCure's earnings call?

AtriCure will be holding an earnings conference call on Wednesday, May 1st at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were AtriCure's earnings last quarter?

AtriCure, Inc. (NASDAQ:ATRC) issued its quarterly earnings data on Thursday, February, 15th. The medical device company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.22) by $0.01. The medical device company earned $106.50 million during the quarter, compared to analysts' expectations of $103.68 million. AtriCure had a negative net margin of 7.62% and a negative trailing twelve-month return on equity of 7.55%. The company's quarterly revenue was up 21.0% on a year-over-year basis. During the same period last year, the firm earned ($0.09) earnings per share.

What ETF holds AtriCure's stock?

iShares U.S. Medical Devices ETF holds 322,356 shares of ATRC stock, representing 0.14% of its portfolio.

What guidance has AtriCure issued on next quarter's earnings?

AtriCure updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of -0.820--0.740 for the period, compared to the consensus EPS estimate of -0.690. The company issued revenue guidance of $459.0 million-$466.0 million, compared to the consensus revenue estimate of $455.9 million.

What is Michael Carrel's approval rating as AtriCure's CEO?

38 employees have rated AtriCure Chief Executive Officer Michael Carrel on Glassdoor.com. Michael Carrel has an approval rating of 100% among the company's employees. This puts Michael Carrel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at AtriCure to a friend.

What other stocks do shareholders of AtriCure own?
Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (1.49%), Diversified Trust Co (0.07%), Los Angeles Capital Management LLC (0.06%), Wesbanco Bank Inc. (0.03%) and Norden Group LLC (0.03%). Insiders that own company stock include Angela L Wirick, Angela L Wirick, David D Jr Grumhaus, Douglas J Seith, Justin J Noznesky, Karen Prange, Karl S Dahlquist, Maggie Yuen, Mark A Collar, Mark A Collar, Regina E Groves, Salvatore Privitera, Scott William Drake, Sven Wehrwein, Tonya Austin and Vinayak Doraiswamy.
View institutional ownership trends
.

How do I buy shares of AtriCure?

Shares of ATRC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does AtriCure have any subsidiaries?
The following companies are subsidiares of AtriCure: SentreHEART.
Read More
This page (NASDAQ:ATRC) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners